|
|
|
| Influence of Qizhen Capsule Adjuvant Therapy on T Lymphocyte Subsets Tumor Markers and Prognosis of Breast Cancer |
| XU Mengshan, et al |
| Breast Tumor Center, Hainan Cancer Hospital,Hainan Haikou 570100, China |
|
|
|
|
Abstract Objective: To explore the effect of Qizhen capsule on T lymphocyte subsets,tumor markers and prognosis of breast cancer. Methods: Eighty patients with breast cancer who received treatment at our hospital from January 2019 to January 2021 were selected for this study.They were randomly divided into a control group and an observation group,with 40 patients in each group.Both groups received the EC chemotherapy intervention (cyclophosphamide+doxorubicin+fluorouracil).Additionally,the observation group received Qizhen capsule as oral treatment.Both groups were treated continuously for 6 weeks.The study compared the blood routine status,T lymphocyte subpopulations (CD3+,CD4+,CD8+),and tumor marker indicators (carcinoembryonic antigen (CEA),carbohydrate antigen 153 (CA153),and cancer antigen 125 (CA125) levels between the two groups.As of the follow-up on February 28,2023,the study analyzed the difference in median survival time between the two groups. Results: Before treatment,there were no significant differences in red blood cells,white blood cells,and platelets between the two groups (P>0.05).After treatment,the difference in white blood cell and platelet counts before and after treatment in the observation group was greater than in the control group (P<0.05).Before treatment,there were no significant differences in CD3+,CD4+,and CD8+ between the two groups (P>0.05).After treatment,the difference in CD3+ and CD4+ before and after treatment in the observation group was greater than in the control group (P<0.05).Before treatment,there were no significant differences in CEA,CA153,and CA125 between the two groups (P>0.05).After treatment,CEA,CA153,and CA125 were decreased in both groups,with the difference in CEA,CA153,and CA125 before and after treatment in the observation group being greater than in the control group (P<0.05).As of February 28,2023,4 patients in the observation group experienced disease recurrence and metastasis,while 11 patients in the control group experienced recurrence and metastasis.Compared with the control group,the observation group had a higher disease-free survival rate,and the survival advantage was more pronounced (χ2=7.195,P=0.007).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Adjuvant treatment with Qizhen capsule can improve the T lymphocyte subsets,tumor markers,and postoperative survival of breast cancer patients,and the treatment is safe.
|
|
|
|
|
|
[1] 孟轲,耿一萌,杨珍珍,等.自噬相关基因对老年女性乳腺癌预后预测的价值[J].郑州大学学报(医学版),2022,57(2):181-185.
[2] 孙晓红,孙晓娜,位菊峰,等.乳腺癌改良根治术后加速康复外科指导功能锻炼对上肢功能的改善效果[J].实用临床医药杂志,2021,25(4):81-85.
[3] 郑国红,曹钢,杨海芳,等.放射治疗对乳腺癌患者心脏损伤指标影响的Meta分析[J].河北医科大学学报,2022,43(5):530-535.
[4] 王晓娇,练孝春,韩涛,等.新辅助化疗联合保乳术对早期乳腺癌患者的临床运用分析[J].河北医学,2022,28(11):1887-1891.
[5] 王平,彭永强,王晓东,等.新辅助化疗EC方案联合保乳手术治疗乳腺癌患者对免疫功能及近期预后的影响[J].湖南师范大学学报:医学版,2021,18(4):201-204.
[6] 安彦波,王晓亚,张静,等.芪珍胶囊对胃肠恶性肿瘤肺转移的治疗效果[J].河北医药,2021,43(9):1335-1338.
[7] 李德錄,郑莹,李敏,等.上海市推行《中国常见恶性肿瘤诊治规范》(乳腺癌)的效果评估[J].中国癌症杂志,2004,14(5):458-461.
[8] 王约翰.MR评估乳腺癌新辅助化疗疗效的应用[J].实用放射学杂志,2021,37(4):675-678.
[9] 徐闻博,沈建国,滕荣跃.淋巴结阴性的早期三阴性乳腺癌不同辅助治疗策略的预后分析[J].癌症,2021,40(2):82-89.
[10] 单臻,林颖.三阴性乳腺癌辅助及新辅助治疗方案探索[J].临床肿瘤学杂志,2021,26(11):1036-1045.
[11] 唐鹏.芪珍胶囊对乳腺癌化疗患者 T细胞亚群的影响[J].实用癌症杂志,2016,31(7):1084-1087.
[12] 郭丹丹,郭铖洁,桑婷婷,等.芪珍胶囊抗结肠癌的作用机制研究[J].中草药,2021,52(10):2967-2977.
[13] Mayer,erica l.,dueck,amylou c.,martin,miguel,et al.Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS):interim analysis of a multicentre,open-label,randomised,phase 3 study[J].The lancet oncology,2021,22(2):212-222.
[14] 谢炜丽,王兴中,张桂连.加味逍遥散治疗更年期乳腺癌化疗后伴抑郁患者的临床疗效及对T淋巴细胞亚群水平的影响[J].中国妇幼保健,2022,37(9):1562-1565.
[15] 胡一迪,谢燊侠,张辉,等.芪珍胶囊联合多西他赛注射液对乳腺癌患者新辅助化疗的效果及安全性评价[J].中国生化药物杂志,2017,37(3):144-146,149. |
|
|
|
2023, Vol. 29 
